Mark Kaplan is a Rheumatology/Immunology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
36100 N Brookside Dr Ste 203
Gurnee, IL 600314573
Telephone
847-855-1570Provider last certified this registry record 9 Sept 2022.
Clinical trials
- ProStat Supplementation in Dialysis Patients
Sponsor: Fresenius Medical Care North America
- Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients
Sponsor: Fresenius Medical Care North America
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
31 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ARS Pharmaceuticals Operations, Inc.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year202421 payments
- Optinose US, Inc.Program year202414 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
74.6%Histamine-1 Receptor Antagonist24.7%Azelastine Hcl73%Levocetirizine Dihydrochloride28%Part D≥69 patientsCorticosteroid22.9%Fluticasone Propionate28%Trelegy Ellipta27%Breo Ellipta13%Breztri Aerosphere9%Pulmicort Flexhaler9%Budesonide-Formoterol Fumarate8%Symbicort5%Part D<11 patients+ 3 more classes in this area
Nervous system
15.3%Gabapentinoids7.7%Gabapentin100%Part D≥18 patientsTricyclic Antidepressant6.2%Amitriptyline Hcl66%Desipramine Hcl34%Part D<11 patients+ 1 more class in this area
Dermatology
7.3%Interleukin-4 Receptor alpha Antagonist4.7%Dupixent Syringe69%Dupixent Pen31%Part D<11 patientsCorticosteroid2.7%Triamcinolone Acetonide100%Part D≥15 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”